Plant ID: NPO4124
Plant Latin Name: Dimocarpus longan
Taxonomy Genus: Dimocarpus
Taxonomy Family: Sapindaceae
NCBI TaxonomyDB:
128017
Plant-of-the-World-Online:
n.a.
Malaysia; India
GPR35; | |
RECQL; TDP1; AKR1B1; HPGD; APEX1; POLB; | |
TEK; INSR; MET; KDR; EGFR; NUAK1; SRC; IGF1R; CSNK2A1; | |
CA12; CA7; CA4; | |
KDM4E; | |
FUT7; | |
SLC22A6; | |
SMAD3; LMNA; HSPA1A; |
Cytochrome P450 Enzymes: |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 1.441E-10 | 3.137E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.509E-09 | 1.115E-05 | EGFR, IGF1R, INSR, KDR, SRC |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.996E-08 | 5.624E-05 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, LMNA, SMAD3, SRC, TEK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.600E-07 | 1.162E-04 | EGFR, INSR, KDR |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 6.095E-07 | 3.493E-04 | EGFR, IGF1R, INSR, KDR, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 8.222E-07 | 3.895E-04 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.625E-07 | 3.996E-04 | CA12, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.322E-06 | 5.430E-04 | EGFR, INSR, MET, SRC, TEK |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.608E-06 | 6.253E-04 | APEX1, POLB |
BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 2.363E-06 | 8.552E-04 | EGFR, IGF1R, INSR, KDR, MET, SRC, TEK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.565E-06 | 1.115E-03 | CA4, EGFR, HPGD, SLC22A6, TEK |
BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 6.152E-06 | 1.648E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.068E-05 | 2.236E-03 | AKR1B1, APEX1, EGFR, SRC |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.329E-05 | 2.731E-03 | CA12, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.361E-05 | 2.769E-03 | EGFR, INSR, KDR, SMAD3, SRC |
BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.661E-05 | 3.218E-03 | AKR1B1, CA12, CA7, EGFR, GPR35, INSR, MET, SMAD3 |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 1.976E-05 | 3.616E-03 | EGFR, INSR, SMAD3 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.449E-05 | 4.336E-03 | CA12, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 2.677E-05 | 4.589E-03 | AKR1B1, APEX1, EGFR, KDR, SRC |
BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 2.760E-05 | 4.695E-03 | APEX1, CSNK2A1, EGFR, HPGD, SLC22A6, SRC, TEK |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 3.364E-05 | 5.507E-03 | EGFR, POLB |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 4.806E-05 | 7.370E-03 | EGFR, IGF1R, INSR |
MF | Unclassified; | GO:0032403; protein complex binding | 4.888E-05 | 7.443E-03 | APEX1, EGFR, IGF1R, INSR, KDR, SMAD3, SRC |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.234E-12 | 3.331E-10 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.387E-09 | 2.774E-07 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.219E-08 | 7.618E-07 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.959E-07 | 7.619E-06 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.167E-06 | 5.436E-05 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.618E-06 | 5.946E-05 | SRC, KDR, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 4.508E-06 | 5.946E-05 | SRC, KDR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.722E-06 | 8.837E-05 | INSR, TEK, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.121E-05 | 2.185E-04 | SMAD3, INSR, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.835E-05 | 6.400E-04 | INSR, HSPA1A, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.160E-06 | 2.389E-05 | CA12, CA4, CA7 |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.195E-05 | 7.034E-04 | SRC, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 9.323E-05 | 7.386E-04 | MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.500E-04 | 1.839E-03 | SRC, EGFR, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.390E-03 | 8.155E-03 | SMAD3, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.425E-03 | 8.155E-03 | HPGD, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.194E-03 | 7.685E-03 | SRC, EGFR |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.771E-03 | 9.602E-03 | INSR, IGF1R |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 7.734E-04 | 5.311E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; EGFR; SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | AML | NA | KDR; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |